JPRN-UMIN000001437已完成2 期
Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer. - JACCRO CC-03
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Contraindications of using CPT-11, Bevacitumab, 5-FU and Leucovorin (2) Having double or more cancers within 5 yeras. (3).Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant. (4) Any subject judged by the investigator to be unfit for any reason to participate in the study
研究者
相似试验
已完成
2 期
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.Recurrent or metastatic colorectal cancerJPRN-UMIN000004219Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology40
已完成
2 期
Phase II Study of FOLFIRI Plus Bevacizumab (AVASIRI) in Patients as Second Line Chemotherapy of Unresectable Colorectal CancerColorectal CancerJPRN-UMIN000001060ational Cancer Center Hospital, Gastrointestinal Oncology Division35
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
进行中（未招募）
不适用
patients with colorectal carcinoma compared to patients with normal LDH serum levelspatients treated with first-line chemotherapy and bevacizumab will be prospectively stratified according to LDH serum levelsEUCTR2012-005048-46-ITFondazione GISCAD
招募中
2 期
A phase II trial of FOLFOXIRI+Bevacizumab as preoperative chemotherapy for locally advanced lower rectal cancerower rectal cancerJPRN-UMIN000031028Kobe University Graduate School of Medicine40